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Significant variability has been observed in the development and severity of neonatal
abstinence syndrome (NAS) among neonates exposed to prenatal opioids. Since maternal opioid dose does not appear to correlate directly with neonatal outcome, maternal,
placental, and fetal genomic variants may play important roles in NAS. Previous studies
in small cohorts have demonstrated associations of variants in maternal and infant
genes that encode the μ-opioid receptor (OPRM1), catechol-O-methyltransferase
(COMT), and prepronociceptin (PNOC) with a shorter length of hospital stay and less
need for treatment in neonates exposed to opioids in utero. Consistently falling genomic
sequencing costs and computational approaches to predict variant function will permit
unbiased discovery of genomic variants and gene pathways associated with differences
in maternal and fetal opioid pharmacokinetics and pharmacodynamics and with placental opioid transport and metabolism. Discovery of pathogenic variants should permit
better delineation of the risk of developing more severe forms of NAS. This review
provides a summary of the current role of genomic factors in the development of NAS
and suggests strategies for further genomic discovery.
Keywords: genomics, opioids, neonatal abstinence syndrome, precision medicine, treatment

INTRODUCTION
An epidemic of neonatal abstinence syndrome (NAS) currently exists due to dramatic increases
in prenatal opioid exposure. Significant variability has been noted in the incidence and severity of NAS among neonates exposed to prenatal opioids. The promise of precision medicine
has prompted increasing interest in discovery of genomic variants that could better predict the
development and severity of NAS and suggest new therapeutic approaches for both prevention
and treatment (1–3). Although the prevalence of NAS has remained stable between 1997 and
2011 in England and Australia (4), NAS has increased significantly in the United States over
the past several years from 7 cases/1,000 neonatal intensive care unit admissions in 2004 to 27
cases/1,000 admissions in 2013 (5). The economic (now >$1.5 billion per year in the United
States), emotional, and social burdens associated with NAS are substantial due to the frequent
need for prolonged hospitalizations and the increased risk of adverse long-term neonatal neurodevelopmental outcomes (6, 7). While most neonates developing NAS respond well to treatment with opioids, a subset of exposed infants will require additional pharmacological therapy
(e.g., phenobarbital, clonidine) and longer hospitalizations (1, 8–10). Multiple environmental factors such as maternal socioeconomic status and prenatal exposure to other illicit and prescription
drugs contribute to neonatal outcome. Precision medicine initiatives involving genomic-based
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prediction of NAS severity are particularly attractive due to
previous associations between individual genomic variants
and outcome, poor predictive accuracy of most clinical and
demographic factors, and rapidly falling sequencing costs
(2, 11, 12). Epigenetic regulation of genes associated with maternal and fetal drug metabolism and placental drug metabolism
and transport may also contribute to disease severity and have
been reviewed previously (13).

of disease severity will require race-/ethnicity-based stratification and assessment of admixture (Table 1). Functional
annotation and prediction programs may permit improved
risk evaluation of individual SNPs (18) and comparison of the
contributions of maternal and infant drug metabolism to risk
of NAS. Finally, the complexity of the genomic architecture,
developmental regulation of gene expression, and the contributions of maternal medications and confounding diagnoses will
require further refinement of SNP-based strategies before they
can be used clinically.

ASSOCIATIONS OF GENOMIC VARIANTS
WITH NAS RISK AND SEVERITY

FUTURE DIRECTIONS FOR GENOMICS
OF NAS RESEARCH

Based on twin studies, opioid addiction is heritable (14).
This heritability has prompted case–control studies that have
examined the association of several single-nucleotide polymorphisms (SNPs) in genes known to be involved in opioid
metabolism and addiction with length of hospitalization, need
for pharmacologic treatment, and total days of opioid treatment in neonates with NAS (12) (Table 1). Results suggest that
SNPs in both mother and infant are associated with severity
of NAS (2, 15–17). For example, in studies of opioid-exposed
newborn infants and their mothers (2, 15), SNPs in maternal
and infant genes that encode the μ-opioid receptor (OPRM1),
catechol-O-methyltransferase (COMT), and prepronociceptin
(PNOC) were associated with differences in neonatal outcomes
(length of hospitalization and reduced need for treatment with
two medications). While the SNPs chosen for study are known
to have important physiologic roles in opioid drug response
and withdrawal in adults, the effect sizes of these SNPs have
been modest and have not had a significant impact on clinical
practice (2, 16). In addition, differences in allele frequencies
suggest that the use of a limited number of SNPs as biomarkers

Extension of current SNP-based studies of the genomics of
NAS may benefit from leveraging available, diverse large exome
and genome databases (e.g., http://gnomad.broadinstitute.
org/) to evaluate the predicted function and frequency of both
common and rare SNPs in genes known to be associated with
heritable addiction or alterations in drug metabolism. Falling
sequencing costs will permit complete genomic resolution for
discovery of clinically actionable genomic variants in individual mother/infant dyads. This approach should avoid the
need to rely on linkage disequilibrium or imputation. Unbiased
whole exome or genome sequencing would permit the evaluation of the contributions of rare variants in both recognized
and unrecognized genes to NAS severity. The statistical challenges associated with rare variant discovery may be partially
addressed by using family study design (e.g., twin studies)
to reduce the contributions of highly diverse genomic backgrounds to phenotype and multiple confounding co-variables
present in case–control studies. Examining infants with the

Table 1 | Genes associated with NAS phenotype.
Gene

SNP

Genotype

Associated NAS phenotype

Annotation

CADD
scorec

Allele frequencies
EA

Afr

Latino

OPRM1

rs1799971

G allelea

Less likely to receive treatment; shortened length of stay

Missense
Asn133Asp

24.1

0.13

0.03

0.21

COMT

rs4680

G allelea

Missense
Val158Met

11.4

0.48

0.69

0.6

rs4680
rs740603
rs740603

G alleleb
A allelea
A alleleb

Less likely to receive treatment with two or more medications;
shortened length of stay
Less likely to receive treatment with two medications
Less likely to receive pharmacological treatment; shortened length of stay
Less likely to receive any pharmacological treatment

11.4
0.2
0.2

0.49

0.56

0.61

rs351776
rs351776
rs2614095
rs4732636

A allelea
A alleleb
A allelea
A allelea

More likely to be treated with two medications; longer length of stay
More likely to receive treatment with two medications; longer length of stay
More likely to be treated with two medications
Less likely to receive medication treatment

Intronic

0.44

0.78

0.69

Intronic
Upstream

1.3
1.3
2.9
6.3

0.46
0.28

0.11
0.1

0.27
0.36

OPRK1

rs702764

C allelea

More likely to receive treatment with two medications

Synonymous

0.4

0.13

0.49

0.28

OPRD1

rs204076

A alleleb

More likely to receive treatment with two medications; longer length of stay

Downstream

5.6

0.66

0.83

0.82

DRD2

rs1799732

Deletion

Less likely to require treatment with medication

Upstream

N/A

0.1

0.5

0.12

PNOC

Intronic

Infant allele.
Maternal allele.
c
Combined annotation-dependent depletion (17).
EA, European–American; Afr, African; N/A, not applicable (frame shift).
a

b
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extremes of NAS severity may also improve statistical power
to identify relevant genomic variants (19). A review of copy
number and structural variant databases to identify individuals
who are haploinsufficient for specific genes might also provide a
strategy to evaluate functional impact of loss of function alleles
(20). Standard phenotyping that incorporates predictions of
functional impact on the metabolism of opioids, as has been
proposed for the cytochrome P450 genes, along with currently
accepted measures of NAS severity may also be useful (21, 22).
Developmental regulation of relevant drug metabolizing and
placental transport genes will likely require model systems for
testing gestational age-specific effects of individual variants
(23, 24). Finally, development of statistical approaches that
incorporate confounding variables like breastfeeding, smoking,
and use of protocol-driven medication weaning strategies (25)
will be important to compare the contributions of genomic
variants with these kinds of clinical variables. Application of
precision medicine to the problem of NAS could benefit the
many adults and neonates exposed to opioids by providing
individualized risk prediction and leveraging discovery of
candidate genes for development of novel therapeutic strategies
(3, 12). For example:

(D) With high-risk profiles identified in neonates, could we
administer low doses of opioids immediately after birth and
limit the development and severity of NAS?
(E) If lower risk profiles are identified in neonates, could we
send them home earlier and carefully follow them up as an
outpatient?
(F) Can pharmacogenomics identify optimal treatment strategies (i.e., best practices) for the mother and her neonate?
(G) If genetic risk factors can be combined with clinical and
demographic variables, can we develop “risk assessment”
models that can be applied to neonates, older children, and
adults to determine the risk of addiction following exposure
to opioids (e.g., low, medium, high)?
These are some of the potential benefits of a more precision medicine-guided approach that could be adopted with
rapid development of novel genomics methodologies. What is
most important is sufficient funding, and legislative efforts are
currently driving this innovation and offer a path forward to
address NAS in this highly vulnerable population.

AUTHOR CONTRIBUTIONS

(A) If we can establish high-risk genetic profiles in young
women, can we then limit opioid exposure?
(B) Can we establish low-risk genetic profiles in young women
and safely wean them off their medication-assisted treatment without an increased risk of relapse?
(C) If high-risk profiles are found in pregnant women, can we
intervene and modify risk factors such as limiting cigarette
smoking and polypharmacy?
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